Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis

Annals of Neurology

Volumn 71, Issue 2, 2012, Pages 227-244

  Manrique Hoyos, Natalia ^a   Jürgens, Tanja ^b,c,d   Grønborg, Mads ^e   Kreutzfeldt, Mario ^b,c,d   Schedensack, Mariann ^b,c   Kuhlmann, Tanja ^f   Schrick, Christina ^b,c   Brück, Wolfgang ^b,c   Urlaub, Henning ^e   Simons, Mikael ^a,d   Merkler, Doron ^b,c,d  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CUPRIZONE; MYELIN;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOCOMOTION; MOTOR PERFORMANCE; MOTOR SKILL SEQUENCE; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE FIBER; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; REMYELINIZATION; SPHEROID CELL;

AGING; ANIMALS; AXONS; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; MOTOR SKILLS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MYELIN SHEATH; TIME FACTORS;

EID: 84857539822     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22681     Document Type: Article

References (75)

1. Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129: 1940-1952. (Pubitemid 44289061)
2. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285. (Pubitemid 28065253)
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG,. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
4. Bjartmar C, Trapp B,. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003; 5: 157-164.
5. Compston A, Coles A,. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
6. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-2212.
7. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000; 123: 1174-1183. (Pubitemid 30312109)
8. Ferguson B, Matyszak MK, Esiri MM, Perry VH,. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399. (Pubitemid 27153632)
9. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-276. (Pubitemid 30641742)
10. Brück W, Kuhlmann T, Stadelmann C,. Remyelination in multiple sclerosis. J Neurol Sci 2003; 206: 181-185. (Pubitemid 36143725)
11. Franklin RJM, ffrench-Constant C,. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-855.
12. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
13. Miller DH, Leary SM,. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6: 903-912. (Pubitemid 47405002)
14. Leary SM, Thompson AJ,. Primary progressive multiple sclerosis: current and future treatment options. 19 vol. Auckland, New Zealand: Adis International, 2005: 8.
15. Kremenchutzky M, Rice GPA, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584-594. (Pubitemid 43278221)
16. Vukusic S, Confavreux C,. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007; 20: 269-274. (Pubitemid 46743107)
17. Matsushima GK, Morell P,. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001; 11: 107-116.
18. Blakemore WF,. Demyelination of the superior cerebellar peduncle in the mouse induced by cuprizone. J Neurol Sci 1973; 20: 63-72.
19. Blakemore WF, Franklin RJM,. Remyelination in experimental models of toxin-induced demyelination. In: Advances in multiple sclerosis and experimental demyelinating diseases. Curr Top Microbiol Immunol, 2008; 193-212.
20. Liebetanz D, Merkler D,. Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. Exp Neurol 2006; 202: 217-224. (Pubitemid 44344263)
21. Merkler D, Boretius S, Stadelmann C, et al. Multicontrast MRI of remyelination in the central nervous system. NMR Biomed 2005; 18: 395-403. (Pubitemid 41410360)
22. Mason JL, Langaman C, Morell P, et al. Episodic demyelination and subsequent remyelination within the murine central nervous system: changes in axonal calibre. Neuropathol Appl Neurobiol 2001; 27: 50-58. (Pubitemid 32293591)
23. Hiremath MM, Saito Y, Knapp GW, et al. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 1998; 92: 38-49. (Pubitemid 29015988)
24. NikiÄ I, Merkler D, Sorbara C, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495-499.
25. Coetzee T, Fujita N, Dupree J, et al. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 1996; 86: 209-219. (Pubitemid 26286104)
26. Norton WT, Poduslo SE,. Myelination of rat brain: method of myelin isolation. J Neurochem 1973; 21: 749-757.
27. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
28. Thingholm TE, Larsen MR,. The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. In: de Graauw M, ed. Phospho-proteomics. Methods in Molecular Biology. Vol. 527. New York: Humana Press, 2009: 57-66.
29. Pruitt KD, Tatusova T, Maglott DR,. NCBI Reference Sequence Project: update and current status. Nucleic Acids Res 2003; 31: 34-37. (Pubitemid 36150328)
30. Perkins DN, Pappin DJC, Creasy DM, Cottrell JS,. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20: 3551-3567. (Pubitemid 30007252)
31. Guo Y, Singleton PA, Rowshan A, et al. Quantitative proteomics analysis of human endothelial cell membrane rafts. Mol Cell Proteomics 2007; 6: 689-696.
32. Martin B, Brenneman R, Becker KG, et al. iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease. PLoS One 2008; 3: e2750.
33. Kassie F, Anderson LB, Higgins L, et al. Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice. Carcinogenesis 2008; 29: 610-619. (Pubitemid 351404879)
34. Graham R, Sharma M, Ternan N, et al. A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol 2007; 8: R110.
35. The UniProt Consortium. The Universal Protein Resource (UniProt). Nucleic Acids Res 2008; 36: D190-D195.
36. Krogh A, Larsson B, von Heijne G, Sonnhammer ELL,. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001; 305: 567-580. (Pubitemid 33032862)
37. Käll L, Krogh A, Sonnhammer ELL,. A combined transmembrane topology and signal peptide prediction method. J Mol Biol 2004; 338: 1027-1036. (Pubitemid 38542831)
38. Hibbits N, Pannu R, Wu TJ, Armstrong RC,. Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN Neuro 2009;1pii:e00013.
39. Schalomon PM, Wahlsten D,. Wheel running behavior is impaired by both surgical section and genetic absence of the mouse corpus callosum. Brain Res Bull 2002; 57: 27-33. (Pubitemid 34097767)
40. Hirano A,. The role of electron microscopy in neuropathology. Acta Neuropathol 2005; 109: 115-123.
41. Grassiot B, Desgranges B, Eustache F, Defer G,. Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol 2009; 256: 1397-1412.
42. Siffrin V, Vogt J, Radbruch H, et al. Multiple sclerosis-candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010; 33: 202-210.
43. Kutzelnigg A, Lassmann H,. Cortical lesions and brain atrophy in MS. J Neurol Sci 2005; 233: 55-59. (Pubitemid 40804816)
44. Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676-1695.
45. Lappe-Siefke C, Goebbels S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003; 33: 366-374. (Pubitemid 36278853)
46. Griffiths I, Klugmann M, Anderson T, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998; 280: 1610-1613. (Pubitemid 28278256)
47. Yin X, Crawford TO, Griffin JW, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci 1998; 18: 1953-1962. (Pubitemid 28141401)
48. Trapp BD, Nave K-A,. Multiple sclerosis: an immune or neurodegenerative disorder? Ann Rev Neurosci 2008; 31: 247-269.
49. Clements R, McDonough J, Freeman E,. Distribution of parvalbumin and calretinin immunoreactive interneurons in motor cortex from multiple sclerosis post-mortem tissue. Exp Brain Res 2008; 187: 459-465.
50. Irvine KA, Blakemore WF,. Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 2006; 175: 69-76. (Pubitemid 43765747)
51. Irvine KA, Blakemore WF,. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008; 131: 1464-1477. (Pubitemid 351806463)
52. Lindner M, Fokuhl J, Linsmeier F, et al. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 2009; 453: 120-125.
53. Lindner M, Heine S, Haastert K, et al. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol Appl Neurobiol 2008; 34: 105-114.
54. Ludwin SK, Maitland M,. Long-term remyelination fails to reconstitute normal thickness of central myelin sheaths. J Neurol Sci 1984; 64: 193-198. (Pubitemid 14111142)
55. Kerschensteiner M, Bareyre FM, Buddeberg BS, et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med 2004; 200: 1027-1038. (Pubitemid 39431127)
56. Trapp BD, Ransohoff RM, Fisher E, Rudick RA,. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48-57. (Pubitemid 29058945)
57. Johnson ES, Ludwin SK,. The demonstration of recurrent demyelination and remyelination of axons in the central nervous system. Acta Neuropathol 1981; 53: 93-98. (Pubitemid 11167544)
58. Confavreux C, Vukusic S, Moreau T, Adeleine P,. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
59. Nave K-A, Trapp BD,. Axon-glial signaling and the glial support of axon function. Ann Rev Neurosci 2008; 31: 535-561.
60. Peters A,. The effects of normal aging on myelin and nerve fibers: a review. J Neurocytol 2002; 31: 581-593. (Pubitemid 37386651)
61. Peters A, Morrison JH, Rosene DL, Hyman BT,. Are neurons lost from the primate cerebral cortex during normal aging? Cereb Cortex 1998; 8: 295-300. (Pubitemid 28280735)
62. Peters A,. Age-related changes in oligodendrocytes in monkey cerebral cortex. J Comp Neurol 1996; 371: 153-163. (Pubitemid 26250519)
63. Bartzokis G,. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004; 25: 5-18. (Pubitemid 37522186)
64. Xi MC, Liu RH, Engelhardt JK, et al. Changes in the axonal conduction velocity of pyramidal tract neurons in the aged cat. Neuroscience 1999; 92: 219-225. (Pubitemid 29249032)
65. Felts PA, Baker TA, Smith KJ,. Conduction in segmentally demyelinated mammalian central axons. J Neurosci 1997; 17: 7267-7277. (Pubitemid 27413258)
66. Lasiene J, Matsui A, Sawa Y, et al. Age-related myelin dynamics revealed by increased oligodendrogenesis and short internodes. Aging Cell 2009; 8: 201-213.
67. Ludwin SK, Sternberger NH,. An immunohistochemical study of myelin proteins during remyelination in the central nervous system. Acta Neuropathol 1984; 63: 240-248. (Pubitemid 14111834)
68. Devaux J, Gow A,. Tight junctions potentiate the insulative properties of small CNS myelinated axons. J Cell Biol 2008; 183: 909-921.
69. Yool DA, Edgar JM, Montague P, Malcolm S,. The proteolipid protein gene and myelin disorders in man and animal models. Hum Mol Genet 2000; 9: 987-992. (Pubitemid 30216110)
70. Bronstein JM, Chen K, Tiwari-Woodruff S, Kornblum HI,. Developmental expression of OSP/claudin-11. J Neurosci Res 2000; 60: 284-290. (Pubitemid 30253591)
71. Gow A, Southwood CM, Li JS, et al. CNS myelin and sertoli cell tight junction strands are absent in Osp/Claudin-11 null mice. Cell 1999; 99: 649-659. (Pubitemid 30004640)
72. Smith KJ, Blakemore WF, McDonald WI,. Central remyelination restores secure conduction. Nature 1979; 280: 395-396. (Pubitemid 9235207)
73. Duncan ID, Brower A, Kondo Y, et al. Extensive remyelination of the CNS leads to functional recovery. Proc Natl Acad Sci U S A 2009; 106: 6832-6836.
74. Piaton G, Gould RM, Lubetzki C,. Axon-oligodendrocyte interactions during developmental myelination, demyelination and repair. J Neurochem 2010; 114: 1243-1260.
75. Taveggia C, Feltri ML, Wrabetz L,. Signals to promote myelin formation and repair. Nat Rev Neurol 2010; 6: 276-287